myNEO Therapeutics
1 known investors
myNEO develops the ImmunoEngine platform, a modular suite of AI-driven technologies for immune target discovery, prioritization, and optimization, covering personalized neoantigen discovery, codon optimization, construct design, ADA risk prediction, and epitope screening. It serves biologics developers, vaccine and T-cell therapy developers, and pharma partners building immunotherapies including cancer vaccines and biologics.